1. In Vivo
  2. >>Deal-Making

Podcast: Making Asset Acquisition Frictionless Via Digital Marketplace and AI

 
• By David Wild

Israeli start-up 9xchange is removing some of the friction from the asset sale and acquisition process through its digital marketplace. A partnership with BenevolentAI is also helping users identify repurposing or indication expansion opportunities. In Vivo spoke with 9xchange CEO Anat Naschitz and Benevolent AI's Matthew Fujisawa.      

In Vivo Podcast
• Source: Shutterstock

As biopharma companies look to bolster their pipelines, finding a promising asset takes time and meticulous due diligence. An Israeli start-up, 9xchange, is trying to take some of the friction out of the acquisition process through a digital marketplace where buyers are matched with sellers, and vice versa: a dating app for the biopharma industry. 

In this episode of the In Vivo podcast, 9xchange CEO Anat Naschitz talks about the spark that led her to found the company, how it operates and the importance of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By Deanna Kamienski and Maureen Riordan

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

Deals Shaping The Industry, April 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

More from In Vivo

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Deals In Depth: April 2025

 
• By Deanna Kamienski and Maureen Riordan

Four $1bn+ alliances were penned in April, and one exceeded $2bn.